BRIEF-Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial
May 18 Revance Therapeutics Inc
* Revance announces positive top-line 24-week duration of effect results in all three cohorts in RT002 injectable phase 2 cervical dystonia trial
* Company also announced additional positive efficacy results and that RT002 was generally safe and well-tolerated
* In all three cohorts, RT002 injectable appeared to be generally safe and well-tolerated through week 24
* Revance Therapeutics- Based on phase 2 results, expects to discuss next steps in clinical program with US and EU regulatory agencies later this year Source text for Eikon: Further company coverage:
British Airways suffers flight delays after global IT outage
LONDON, May 27 British Airways flights in Britain were being delayed and passengers were suffering long waits at airports on Saturday because of a global system outage, the airline said.
UPDATE 4-Chipotle says hackers hit most restaurants in data breach
May 26 Hackers used malware to steal customer payment data from most of Chipotle Mexican Grill Inc's restaurants over a span of three weeks, the company said on Friday, adding to woes at the chain whose sales had just started recovering from a string of food safety lapses in 2015.